- Home
- PCLA vs INKT Comparison
PCLA vs INKT Comparison
Compare PCLA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCLA
- INKT
- Stock Information
- Founded
- PCLA 2008
- INKT 2017
- Country
- PCLA Japan
- INKT United States
- Employees
- PCLA N/A
- INKT N/A
- Industry
- PCLA Building Products
- INKT Medicinal Chemicals and Botanical Products
- Sector
- PCLA Consumer Discretionary
- INKT Health Care
- Exchange
- PCLA Nasdaq
- INKT Nasdaq
- Market Cap
- PCLA 32.3M
- INKT 28.8M
- IPO Year
- PCLA 2025
- INKT 2021
- Fundamental
- Price
- PCLA $3.25
- INKT $62.86
- Analyst Decision
- PCLA
- INKT Strong Buy
- Analyst Count
- PCLA 0
- INKT 2
- Target Price
- PCLA N/A
- INKT $37.50
- AVG Volume (30 Days)
- PCLA 2.4M
- INKT 2.4M
- Earning Date
- PCLA 01-01-0001
- INKT 08-12-2025
- Dividend Yield
- PCLA N/A
- INKT N/A
- EPS Growth
- PCLA N/A
- INKT N/A
- EPS
- PCLA N/A
- INKT N/A
- Revenue
- PCLA $5,475,228.00
- INKT N/A
- Revenue This Year
- PCLA N/A
- INKT N/A
- Revenue Next Year
- PCLA N/A
- INKT N/A
- P/E Ratio
- PCLA N/A
- INKT N/A
- Revenue Growth
- PCLA 40.19
- INKT N/A
- 52 Week Low
- PCLA $0.37
- INKT $4.56
- 52 Week High
- PCLA $9.80
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- PCLA N/A
- INKT 57.39
- Support Level
- PCLA N/A
- INKT $6.80
- Resistance Level
- PCLA N/A
- INKT $7.88
- Average True Range (ATR)
- PCLA 0.00
- INKT 0.40
- MACD
- PCLA 0.00
- INKT 0.02
- Stochastic Oscillator
- PCLA 0.00
- INKT 58.86
About PCLA PicoCELA Inc. American Depositary Shares
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.